Skip to content

Cash ratio at other companies

Amgen logo
AmgenAMGN
0.0×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
3.8×-2.3×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0.8×-0.1×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
4.4×-1.8×
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
0.2×+0.1×
Precigen logo
PrecigenPGEN
0.4×+0.1×

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Calculated from Septerna, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s cash ratio?
Septerna, Inc. (SEPN) reported cash ratio of 0.9× in Q1 2026.
How has Septerna, Inc.'s cash ratio changed year-over-year?
Septerna, Inc.'s cash ratio decreased by 95.4% year-over-year, from 19.7× to 0.9×.
What is the long-term trend for Septerna, Inc.'s cash ratio?
Over 2 years (2023 to 2025), Septerna, Inc.'s cash ratio has grown at a -67.1% compound annual growth rate (CAGR), from 12.8× to 1.4×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.